NCT04754191View on ClinicalTrials.gov

Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Enfortumab vedotin

Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

University of Utah

OTHER

NCT04754191 - Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter